CA2723722A1 - Igf-ii/gf-iie binding proteins - Google Patents

Igf-ii/gf-iie binding proteins Download PDF

Info

Publication number
CA2723722A1
CA2723722A1 CA2723722A CA2723722A CA2723722A1 CA 2723722 A1 CA2723722 A1 CA 2723722A1 CA 2723722 A CA2723722 A CA 2723722A CA 2723722 A CA2723722 A CA 2723722A CA 2723722 A1 CA2723722 A1 CA 2723722A1
Authority
CA
Canada
Prior art keywords
igf
iie
protein
growth hormone
binding
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
CA2723722A
Other languages
English (en)
French (fr)
Inventor
Daniel T. Dransfield
Edward H. Cohen
Timothy Adams
Leah Cosgrove
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Commonwealth Scientific and Industrial Research Organization CSIRO
Dyax Corp
Original Assignee
Commonwealth Scientific and Industrial Research Organization CSIRO
Dyax Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Commonwealth Scientific and Industrial Research Organization CSIRO, Dyax Corp filed Critical Commonwealth Scientific and Industrial Research Organization CSIRO
Publication of CA2723722A1 publication Critical patent/CA2723722A1/en
Abandoned legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/22—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against growth factors ; against growth regulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2299/00—Coordinates from 3D structures of peptides, e.g. proteins or enzymes
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/55—Fab or Fab'
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Organic Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Immunology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Endocrinology (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
CA2723722A 2008-05-09 2009-05-08 Igf-ii/gf-iie binding proteins Abandoned CA2723722A1 (en)

Applications Claiming Priority (7)

Application Number Priority Date Filing Date Title
US5195608P 2008-05-09 2008-05-09
US61/051,956 2008-05-09
US5342708P 2008-05-15 2008-05-15
US61/053,427 2008-05-15
US16318009P 2009-03-25 2009-03-25
US61/163,180 2009-03-25
PCT/US2009/043273 WO2009137758A2 (en) 2008-05-09 2009-05-08 Igf-ii/gf-iie binding proteins

Publications (1)

Publication Number Publication Date
CA2723722A1 true CA2723722A1 (en) 2009-11-12

Family

ID=41265434

Family Applications (1)

Application Number Title Priority Date Filing Date
CA2723722A Abandoned CA2723722A1 (en) 2008-05-09 2009-05-08 Igf-ii/gf-iie binding proteins

Country Status (6)

Country Link
US (1) US20110165145A1 (enExample)
EP (1) EP2296703A4 (enExample)
JP (2) JP5734180B2 (enExample)
AU (1) AU2009244091B2 (enExample)
CA (1) CA2723722A1 (enExample)
WO (1) WO2009137758A2 (enExample)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PE20090368A1 (es) 2007-06-19 2009-04-28 Boehringer Ingelheim Int Anticuerpos anti-igf
EP2349329A4 (en) * 2008-10-14 2012-10-31 Dyax Corp USE OF IGF-II / IGF-II BINDING FOR THE TREATMENT AND PREVENTION OF SYSTEMIC SCLEROSIS ASSOCIATED WITH LUNG FIBROSIS
AR074726A1 (es) 2008-12-12 2011-02-09 Boehringer Ingelheim Int Anticuerpos anti-igf (factor de crecimiento insulinico)
US9150644B2 (en) 2011-04-12 2015-10-06 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Human monoclonal antibodies that bind insulin-like growth factor (IGF) I and II
US20140255413A1 (en) 2013-03-07 2014-09-11 Boehringer Ingelheim International Gmbh Combination therapy for neoplasia treatment
KR101843248B1 (ko) * 2015-03-17 2018-03-29 고려대학교 세종산학협력단 흉선 기질 림프단백질 매개 신호전달을 제어하는 펩타이드 유도체 및 이를 포함하는 알러지 및 천식 질환 예방 및 치료용 약학 조성물
US10469309B1 (en) * 2016-04-28 2019-11-05 Servicenow, Inc. Management of computing system alerts

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2058041A1 (en) 1990-06-27 1991-12-28 Katsuichi Sakano Anti-igf-ii monoclonal antibody
JP3213359B2 (ja) * 1990-12-21 2001-10-02 第一製薬株式会社 抗ｉｇｆ−ｉｉモノクローナル抗体
WO2003093317A1 (en) * 2002-04-30 2003-11-13 Kyowa Hakko Kogyo Co., Ltd. Antibody to human insulin-like growth factor
US20060263362A1 (en) * 2003-08-21 2006-11-23 Atsushi Ochiai Cancer metastasis inhibitor
JPWO2005027970A1 (ja) * 2003-09-24 2007-11-15 協和醗酵工業株式会社 癌治療用医薬
US7498415B2 (en) * 2003-09-24 2009-03-03 Kyowa Hakko Kogyo Co., Ltd. Recombinant antibody against human insulin-like growth factor
US7612179B2 (en) * 2003-11-28 2009-11-03 Astrazeneca Ab antibodies binding to a C-terminal fragment of apoliopoprotein E
JP5054385B2 (ja) * 2004-02-19 2012-10-24 ダイアックス、コープ 立体配座特異的抗体
AU2005271523B2 (en) * 2004-08-03 2011-09-15 Dyax Corp. hk1-binding proteins
JP5149800B2 (ja) * 2005-08-17 2013-02-20 アメリカ合衆国 Ｉｇｆ−ｉｉに特異的に結合するヒトモノクローナル抗体
DK1979001T3 (da) * 2005-12-13 2012-07-16 Medimmune Ltd Bindingsproteiner, der er specifikke for insulinlignende vækstfaktorer og anvendelser deraf
CN101578297A (zh) * 2006-04-07 2009-11-11 美国政府健康及人类服务部 治疗肿瘤疾病的抗体组合物和方法
US8178091B2 (en) * 2007-05-21 2012-05-15 University Of Washington Compositions and methods for the treatment of respiratory disorders

Also Published As

Publication number Publication date
EP2296703A4 (en) 2012-09-05
US20110165145A1 (en) 2011-07-07
WO2009137758A3 (en) 2010-03-18
EP2296703A2 (en) 2011-03-23
JP5734180B2 (ja) 2015-06-17
AU2009244091A1 (en) 2009-11-12
AU2009244091B2 (en) 2014-11-27
WO2009137758A2 (en) 2009-11-12
JP2011523405A (ja) 2011-08-11
JP2014077020A (ja) 2014-05-01

Similar Documents

Publication Publication Date Title
US8106168B2 (en) Metalloproteinase binding proteins
JP6787795B2 (ja) 抗Ａｘｌ抗体
JP6787796B2 (ja) 抗Ａｘｌ抗体
AU2009303453B2 (en) Use of IGF-II/IGF-IIE binding for the treatment and prevention of systemic sclerosis associated pulmonary fibrosis
AU2009244091B2 (en) IGF-II/GF-IIE binding proteins
KR20150036603A (ko) Rspo3 결합제 및 그의 용도
KR20190021244A (ko) 항-axl 길항성 항체
CA2977621A1 (en) Antibody binding to tfpi and composition comprising the same
US10314909B2 (en) Combination therapy comprising an MMP-14 binding protein
US20220195037A1 (en) Compositions and methods for inhibiting cancer stem cells
HK40096197A (zh) 抗axl拮抗抗体
HK1123740B (en) Metalloproteinase binding proteins

Legal Events

Date Code Title Description
EEER Examination request

Effective date: 20140506

FZDE Discontinued

Effective date: 20161214